Latest News

Investigational Bictegravir–Lenacapavir Single-Tablet Regimen Noninferior to Standard Therapy in Phase 3 ARTISTRY-2 Trial / Image credit: ©Ezume Images/AdobeStock
Investigational Bictegravir–Lenacapavir Single-Tablet Regimen Noninferior to Standard Therapy in Phase 3 ARTISTRY-2 Trial

December 16th 2025

Gilead's ARTISTRY-2 trial shows a promising single-tablet HIV treatment regimen is noninferior to standard therapy, expanding options for virologically suppressed adults.

Primary Care Physician Kevin Hatfield, MD, on Barriers to Daily Oral PrEP Adherence / Image: ©MJH Life Sciences
Primary Care Physician Kevin Hatfield, MD, on Barriers to Daily Oral PrEP Adherence

December 15th 2025

FDA Approves First-in-Class Zolifodacin for Uncomplicated Gonorrhea
FDA Approves First-in-Class Zolifodacin for Uncomplicated Gonorrhea

December 12th 2025

FDA Expands Use of GSK's Gepotidacin as Oral Treatment for Uncomplicated Urogenital Gonorrhea
FDA Expands Use of GSK's Gepotidacin as Oral Treatment for Uncomplicated Urogenital Gonorrhea

December 11th 2025

WHO Safety Panel Updates Evidence Review, Confirms Vaccines Do Not Cause Autism / image credit ©SoniaBonet/stock.adobe.com
WHO Safety Panel Updates Evidence Review, Confirms Vaccines Do Not Cause Autism

December 11th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.